The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock decreased 1.88% or $0.0615 during the last trading session, reaching $3.2185. About 493,875 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since July 12, 2018 and is uptrending. It has outperformed by 16.11% the S&P500.
The move comes after 5 months negative chart setup for the $83.57M company. It was reported on Jul, 12 by Barchart.com. We have $3.09 PT which if reached, will make NASDAQ:IFRX worth $3.34 million less.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.55 EPS, down 358.33 % or $0.43 from last year’s $-0.12 per share. After $-0.43 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 27.91 % negative EPS growth.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on November 08, 2018, also Globenewswire.com with their article: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” published on February 27, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For June 6, 2019 – Benzinga” on June 06, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Full Year 2018 Financial & Operating Results – GlobeNewswire” published on March 28, 2019 as well as Finance.Yahoo.com‘s news article titled: “Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM) – Yahoo Finance” with publication date: June 11, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $83.57 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.